Browse drugs

…reatment in hematologic and solid malignancies. We developed an anti-pan γδ x CD123 bispecific antibody that leverages the cytotoxic potential and innate discriminator…

…he conditional deletion of RORγt in Foxp3 expressing cells upon tamoxifen treatment ( Foxp3 CreERT2 Rorc fl/fl). We tracked the growth of…

…reover, the peripheral masking improves the pharmacokinetics of PD1-reg-IL2v in comparison to non-masked counterparts.Conclusions These resu…

…D79a knockout (KO) mice. Tumors were treated with STING agonist ADU-S100 and anti-LTβR antibody. Tumors were resected 14 days post-treat…

…no-oncology.Methods A 4-plex OmniVUE panel including CD3, Ki67, Granzyme-B and CK/Sox10 was utilized to stain formalin-fixed paraffin-embe…

…al or harvested for flow cytometry 24 hours after anti-CD40 and polyI:C administration.Results This treatment regimen drastically impro…

…metastatic bladder cancer have experienced durable responses to immune checkpoint inhibitors (ICI), the majority of patients do not respond to this therapeu…

…anti-PD1 in a patient derived xenograft (PDX) demonstrated that TA-1 or anti-PD-1 inhibited tumor growth, while combination therapy …

…Background Immune checkpoint inhibitors such as pembrolizumab offer a therapeutic option for head and neck squamous cell carc…

…Background T cell engagers (TCEs) are powerful therapeutics which can kill cells expressing low …

…cell killing efficacy to clinically validated molecules such as tebentafusp.Conclusions In this work, we showcase the discovery and enginee…

…l of HER2-targeting antibodies with intact Fc regions—including trastuzumab—and isotype and payload-only controls were tested. Tumor cell k…